GNMSF
Genmab A/S OTC$261.00
Mkt Cap $16.0B
52w Low $188.80
44.2% of range
52w High $352.00
50d MA $275.89
200d MA $288.04
P/E (TTM)
15.9x
EV/EBITDA
17.1x
P/B
2.7x
Debt/Equity
0.9x
ROE
17.3%
P/FCF
16.4x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$275.89
200d MA
$288.04
Avg Volume
42
About
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amiva…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | 2.81 | 0.51 | -81.9% | 297.25 | -4.3% | -4.3% | -4.3% | -4.3% | -4.3% | -2.4% | — |
| Nov 6, 2025 | AMC | 4.86 | 6.46 | +32.9% | 285.00 | +1.9% | +1.9% | +1.9% | +1.9% | +6.7% | +6.7% | — |
| Aug 7, 2025 | AMC | 3.99 | 5.42 | +35.8% | 216.31 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| May 8, 2025 | AMC | 1.87 | 3.05 | +63.1% | 196.22 | +0.2% | -1.6% | +0.6% | -3.8% | -3.8% | -3.8% | — |
| Feb 12, 2025 | AMC | 0.47 | 5.70 | +1125.0% | 191.84 | +4.6% | +8.2% | +10.0% | +12.7% | +13.7% | +16.3% | — |
| Nov 6, 2024 | AMC | 3.19 | 2.85 | -10.7% | 225.80 | +0.4% | +2.4% | -0.9% | +1.9% | +2.7% | -4.5% | — |
| Aug 8, 2024 | AMC | 3.00 | 3.18 | +6.0% | 260.04 | +2.3% | +0.9% | +0.7% | -1.1% | +0.3% | +2.0% | — |
| May 2, 2024 | AMC | 1.76 | 2.91 | +65.3% | 276.47 | +6.7% | +4.8% | +7.3% | +2.7% | +0.7% | +2.9% | — |
| Feb 14, 2024 | AMC | 3.33 | 3.63 | +9.0% | 272.50 | +7.6% | +5.5% | +5.0% | +5.0% | +5.3% | +5.5% | — |
| Nov 7, 2023 | AMC | 2.96 | 4.63 | +56.4% | 290.75 | +6.6% | +6.6% | +9.0% | +6.8% | +10.1% | +10.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $324.25 | $319.41 | -1.5% | -2.2% | -8.6% | -11.9% | -7.6% | -9.3% |
| Oct 12 | BTIG | Maintains | Buy → Buy | — | $349.70 | $334.00 | -4.5% | -5.4% | -8.8% | -7.3% | -9.3% | -15.3% |
| Sep 25 | Truist | Maintains | Buy → Buy | — | $365.26 | $356.60 | -2.4% | -4.5% | +0.7% | -2.7% | -3.2% | -2.5% |
| Sep 5 | Truist | Maintains | Buy → Buy | — | $384.45 | $386.20 | +0.5% | -1.8% | -1.4% | -1.1% | -0.6% | -4.0% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $371.60 | $372.00 | +0.1% | -1.0% | -0.9% | -2.0% | -3.7% | -2.9% |
| Aug 3 | Morgan Stanley | Maintains | Underweight → Underweight | — | $389.57 | $390.50 | +0.2% | +1.5% | -3.7% | -2.6% | -3.5% | -2.5% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $389.57 | $390.50 | +0.2% | +1.5% | -3.7% | -2.6% | -3.5% | -2.5% |
| Jul 31 | Morgan Stanley | Maintains | Underweight → Underweight | — | $421.26 | $417.60 | -0.9% | -2.6% | -4.9% | -7.5% | -6.1% | -10.9% |
| Jul 30 | Morgan Stanley | Maintains | Underweight → Underweight | — | — | — | — | — | — | — | — | — |
Data updated apr 27, 2026 8:15pm
· Source: massive.com